- 5 FDA decisions to watch in the third quarter of 2026A group of coming decisions could provide important insights into how flexible the agency is willing to be under new leadership.BioPharma Dive · 27d ago↗ source
- Abivax shares surge as worries subside over immune drug’s cancer riskAccording to Abivax, fresh data suggest malignancy rates in its trials were no higher than "background" ones for people with ulcerative colitis, clearing a key safety concern.BioPharma Dive · 27d ago↗ source
- FDA says Zyn can market its pouches as safer than cigarettesThe influence of the alcohol industry on policy, AI Claude for scientists, and more health news from Morning RoundsSTAT · 27d ago↗ source